All In MedTech

Device Trial Radar · NCT07507708

Insulin Delivery With Self-Adjusting Closed-Loop and Behavioral Glycemic Control Enhanced by Prediction

Insulin Delivery With Self-Adjusting Closed-Loop and Behavioral Glycemic Control Enhanced by Prediction (INSIGHT)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

May 14, 2026

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Sue BrownAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Tandem Diabetes Care, Inc.; DexCom, Inc.
First posted
Apr 2, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized cross-over trial comparing AIDANET with Anticipation to AIDANET in FCL without Anticipation. Participants will complete 4 weeks of AID data collection which will be used to establish baseline and initialize the control algorithm. Participants will then be randomized to one of two groups: Group A: AIDANET in FCL with Anticipation (AIDANET+ACL), and Group B: AIDANET in FCL without Anticipation (AIDANET+FCL). The study duration of each group is 4 weeks each. The order of these two phases will be dependent upon randomization.

Conditions

  • Type 1 Diabetes (T1D)

Interventions

  • Automated Insulin Delivery (AID)Device

    Usual Care

  • AIDANET + Fully Closed Loop (FCL)Device

    All participants will use AIDANET in FCL mode with instructions to avoid announcing meal boluses whenever possible during the four weeks.

  • AIDANET + Anticipatory Closed Loop (ACL)Device

    All insulin will be delivered automatically. The algorithm will review past behaviors to determine the amount of insulin that will be needed for a meal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time in range 70-140 mg/dL as computed by the study CGMTime frame: 8 weeks
  2. Time in range 70-140 mg/dL as computed by the study CGMTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Virginia Center for Diabetes Technology

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.